Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in 

-mutant non–small cell lung cancer (NSCLC).

In the double-blind, randomized, placebo-controlled, phase 3 trial, a total of 682 patients with completely resected stage IB to IIIA NSCLC were stratified by stage, 

 mutational status, and race. Patients were randomized 1:1 to receive 80 mg of osimertinib (Tagrisso) once daily or placebo once daily.

The primary end point of the trial, which was disease-free survival in patients with stage II to IIIA disease, was met, Tsuboi says. In these patients, treatment with osimertinib following complete tumor resection reduced the risk of disease recurrence or death by 83% versus placebo, which garnered a lot of excitement in the space, Tsuboi concludes. 

Videos

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer. 

Dr. Tsuboi on Findings From the Phase 3 ADAURA Trial in EGFR+ NSCLC

Clinical Evaluation of ES-NSCLC in Japan

Masahiro Tsuboi, MD, National Cancer Center Hospital East

Articles

Dr. Tsuboi on Findings From the Phase 3 ADAURA Trial in EGFR+ NSCLC

Considerations of Adjuvant Therapy in EGFR+ ES-NSCLC